References
- 1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-30.
- 2. Kopans DB. The positive predictive value of mammography. Am J Roentgenol 1992; 158: 521-6.
- 3. Bird RE, Wallace TW, Yankaskas BC. Analysis of cancer missed at screening mammography. Radiology 1992; 184: 613-7.
- 4. Adriaenssens N, Belsack D, Buyl R, Ruggiero L, Breucq C, De Mey J, Lievens P, Lamote J. Ultrasound elastography as an objective diagnostic measurement tool for lymphoedema of the treated breast in breast cancer patients following breast conserving surgery and radiotherapy. Radiol Oncol 2012; 46: 284-95.
- 5. Zebic-Sinkovec M, Hertl K, Kadivec M, Cavlek M, Podobnik G, Snoj M. Outcome of MRI-guided vacuum-assisted breast biopsy - initial experience at Institute of Oncology Ljubljana, Slovenia. Radiol Oncol 2012; 46: 97-105.
- 6. Agnese DM. Advances in breast imaging. Surg Technol Int 2005; 14: 51-6.
- 7. Scheidhauer K, Walter C, Seemann MD. FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions. Eur J Nucl Med MolImaging 2004; 31: 70-9.
- 8. Thurlimann B, Muller A, Senn HJ. Management of primary breast cancer: an update. Onkologie 2004; 27: 175-9.
- 9. Rausch DR, Hendrick RE. How to optimize clinical breast MR imaging practices and techniques on your 1.5-T system. Radiographics 2006; 26: 1469-84.
- 10. Berg WA, Gutierrez L, NessAiver MS, Carter WB, Bhargavan M, Lewis RS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology 2004; 233: 830-49.
- 11. Winnekendonk G, Krug B, Warm M, Gohring UJ, Mallmann P, Lackner K. Diagnostic value of preoperative contrast-enhanced MR imaging of the breast. Rofo 2004; 176: 688-93.
- 12. Antoch G, Vogt FM, Freudenberg LS, Nazaradeh F, Goehde SC, Barkhausen J, et al. Whole-body dual-modality PET/CTand whole-body MRI for tumor staging in oncology JAMA 2003; 290: 3199-206.
- 13. Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med 2007; 48 (Suppl 1): 78S-88S.
- 14. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology 2007; 242: 360-85.
- 15. Zangheri B, Messa C, Picchio M, Gianolli L, Landoni C, Fazio F. PET/CT and breast cancer. Eur J Nucl Med Mol Imaging 2004; 31 (Suppl 1): 135S-142S.
- 16. Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl MedMol Imaging 2006; 33: 254-62.
- 17. Hodolic M. Role of F-18-choline PET/CT in evaluation of patients with prostate carcinoma. Radiol Oncol 2011; 45: 17-21.
- 18. Kim JS, Jeong YJ, Sohn MH, Jeong HJ, Lim ST, Kim DW, et al. Usefulness of F-18 FDG PET/CT in subcutaneous panniculitis-like T cell lymphoma: disease extent and treatment response evaluation. Radiol Oncol 2012; 46: 279-83.
- 19. Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 2006; 107: 2545-51.
- 20. Beresford M, Lyburn I, Sanghera B, Makris A, Wong WL. Serial integrated 18F-fluorodeoxythymidine PET/CT monitoring neoadjuvant chemotherapeutic response in invasive ductal carcinoma. Breast J 2007; 13: 424-5.
- 21. Li D, Chen JH, Wang J, Ling R, Yao Q, Wang L. Value of fused F-18 FDG PET/ CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer. [in Chinese]. Ai Zheng 2007; 26: 900-4.
- 22. Reddy DH, Mendelson EB. Incorporating new imaging models in breast cancer management. Curr Treat Options Oncol 2005; 6: 135-45.
- 23. Fischer U, Kopka L, Grabbe E. Breast carcinoma: effect of preoperative contrastenhanced MR imaging on the therapeutic approach. Radiology 1999; 213: 881-8.
- 24. Heusner TA, Freudenberg LS, Kuehl H, Hauth AM, Haibach PV, Forsting M, et al. Whole-body PET/CT-mammography for staging breast cancer: initial results. Br J Radiol 2008; 81: 743-8.
- 25. Ko BS, Noh WC, Kang SS, Park BW, Kang EY, Paik NS, et al. Changing patterns in the clinical characteristics of Korean breast cancer from 1996-2010 using an online nationwide breast cancer database. J Breast Cancer 2012; 15: 393-400.
- 26. Andersson I. Mammographic screening and mortality from breast cancer: mammographic screening trial. Br J Med 1998; 297: 943-8.
- 27. Lehman CD, Blume JD, Weatherall P, Thickman D, Hylton N, Warner E, et al. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 2005; 103: 1898-905.
- 28. Friedrich M. MRI of the breast: state of the art. Eur Radiol 1998; 8: 707-25.
- 29. Bedrosian I, Mick R, Orel SG, Schnall MD, Reynolds C, Spitz F, et al. Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer 2003; 98: 468-73.
- 30. Orel SG, Schnall MD. MR imaging of the breast for detection, diagnosis and staging of breast cancer. Radiology 2001; 220: 3-30.
- 31. Schelfout K, Van Goethem M, Kersschot E, Colpaert C, Schelfhout AM, Leyman P, et al. Contrast-enhanced MR imaging of breast lesions and effect on treatment. Eur J Surg Oncol 2004; 30: 501-7.
- 32. Hollingsworth AB, Stough RG, O’Dell CA, Brekke CE. Breast magnetic resonance imaging for preoperative locoregional staging. Am J Surg 2008; 196: 389-97.
- 33. Liberman L, Morris EA, Lee MJ, Kaplan JB, LaTrenta LR, Menell JH, et al. Breast lesions detected on MR imaging: features and positive predictive value. Am J Roentgenol 2002; 179: 171-8.
- 34. Heusner TA, Kuemmel S, Umutlu L, Koeninger A, Freudenberg LS, Hauth AM, et al. Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med 2008; 49: 1215-22.
- 35. Samson DJ, Flamm CR, Pisano ED, Aronson N. Should FDG PET be used to decide whether a patient with an abnormal mammogram or breast finding at physical examination should undergo biopsy? Acad Radiol 2002; 9: 773-83.